Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

DISEASE CHARACTERISTICS:

* Histologically confirmed malignancy

  * Metastatic or unresectable disease
  * Standard curative or palliative measures do not exist, are no longer effective, have been completed, or have been refused
* CEA-positive tumor (either by immunohistochemistry or as demonstrated by elevated CEA \> 50 μg/L)
* No primary brain tumor or brain metastases

PATIENT CHARACTERISTICS:

* WHO performance status 0-1
* Life expectancy ≥ 3 months
* Hemoglobin ≥ 10 g/dL
* Platelet count ≥ 100 x 10\^9/L
* Neutrophil count ≥ 2.0 x 10\^9/L
* Lymphocyte count ≥ 1.0 x 10\^9/L
* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
* ALT/AST ≤ 5 times ULN
* Alkaline phosphatase ≤ 5 times ULN
* Calculated creatinine clearance OR isotope clearance measurement ≥ 50 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy (male patients must use barrier-method contraception)
* LVEF ≥ 50% on MUGA scan (for patients receiving cyclophosphamide)
* ECG and exercise ECG (or stress ECHO) normal (may be abnormal but not clinically significant)
* Urine dipstick normal (may be abnormal but not clinically significant)
* No medical high risk due to nonmalignant systemic disease including active uncontrolled infection
* No known serologically positive hepatitis B, hepatitis C, HIV, or HTLV
* No history of autoimmune disease
* No inflammatory bowel disease
* No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac disease
* No concurrent malignancies originating from other primary sites, except for adequately treated cone-biopsied carcinoma in situ of the cervix uteri or basal cell or squamous cell carcinoma of the skin
* No other condition that, in the investigator's opinion, would make the patient an unsuitable candidate for the clinical trial

PRIOR CONCURRENT THERAPY:

* At least 30 days since prior and no concurrent participation in another clinical trial
* At least 4 weeks since prior and no concurrent radiotherapy (except for palliative reasons \[i.e., control of bone pain\])
* At least 4 weeks since prior and no concurrent endocrine therapy, immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)
* No toxic manifestations of previous treatment, except for alopecia or certain grade 1 toxicities that, in the opinion of the investigator and CRUK (Cancer Research UK), would exclude the patient (e.g., grade 1 neuropathy or grade 1 fatigue)
* No prior major thoracic and/or abdominal surgery from which the patient has not yet recovered
* No prior bone marrow transplant or extensive radiotherapy to \> 25% of bone marrow
* No concurrent systemic steroids or other immunosuppressive therapy
* No other concurrent anticancer therapy or investigational drugs